Showing 1 - 5 results of 5 for search 'Anders Aune Tveita', query time: 0.03s Refine Results
  1. 1
    Interleukin-6 in Allogeneic Stem Cell Transplantation: Its Possible Importance for Immunoregulation and As a Therapeutic Target

    Interleukin-6 in Allogeneic Stem Cell Transplantation: Its Possible Importance for Immunoregulation and As a Therapeutic Target by Tor Henrik Anderson Tvedt, Tor Henrik Anderson Tvedt, Elisabeth Ersvaer, Anders Aune Tveita, Øystein Bruserud, Øystein Bruserud

    Published 2017-06-01
    Get full text
    Article
  2. 2
    National Early Warning Score 2 (NEWS2) on admission predicts severe disease and in-hospital mortality from Covid-19 – a prospective cohort study

    National Early Warning Score 2 (NEWS2) on admission predicts severe disease and in-hospital mortality from Covid-19 – a prospective cohort study by Marius Myrstad, Håkon Ihle-Hansen, Anders Aune Tveita, Elizabeth Lyster Andersen, Ståle Nygård, Arnljot Tveit, Trygve Berge

    Published 2020-07-01
    Get full text
    Article
  3. 3
    Tumor Killing by CD4+ T Cells Is Mediated via Induction of Inducible Nitric Oxide Synthase-Dependent Macrophage Cytotoxicity

    Tumor Killing by CD4+ T Cells Is Mediated via Induction of Inducible Nitric Oxide Synthase-Dependent Macrophage Cytotoxicity by Marte Fauskanger, Ole Audun Werner Haabeth, Frode Miltzow Skjeldal, Frode Miltzow Skjeldal, Bjarne Bogen, Bjarne Bogen, Anders Aune Tveita

    Published 2018-07-01
    Get full text
    Article
  4. 4
    How do CD4+ T cells detect and eliminate tumor cells that either lack or express MHC class II molecules?

    How do CD4+ T cells detect and eliminate tumor cells that either lack or express MHC class II molecules? by Ole Audun Werner Haabeth, Anders Aune Tveita, Marte eFauskanger, Fredrik eSchjesvold, Kristina Berg Lorvik, Peter Olaf Hofgaard, Hilde eOmholt, Ludvig Andre Munthe, Zlatko eDembic, Alexandre eCorthay, Alexandre eCorthay, Alexandre eCorthay, Bjarne eBogen, Bjarne eBogen

    Published 2014-04-01
    Get full text
    Article
  5. 5
    Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial

    Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial by Marius Trøseid, José R. Arribas, Lambert Assoumou, Aleksander Rygh Holten, Julien Poissy, Vida Terzić, Fulvia Mazzaferri, Jesús Rodríguez Baño, Joe Eustace, Maya Hites, Michael Joannidis, José-Artur Paiva, Jean Reuter, Isabel Püntmann, Thale D. J. H. Patrick-Brown, Elin Westerheim, Katerina Nezvalova-Henriksen, Lydie Beniguel, Tuva Børresdatter Dahl, Maude Bouscambert, Monika Halanova, Zoltán Péterfi, Sotirios Tsiodras, Michael Rezek, Matthias Briel, Serhat Ünal, Martin Schlegel, Florence Ader, Karine Lacombe, Cecilie Delphin Amdal, Serge Rodrigues, Kristian Tonby, Alexandre Gaudet, Lars Heggelund, Joy Mootien, Asgeir Johannessen, Jannicke Horjen Møller, Beatriz Diaz Pollan, Anders Aune Tveita, Anders Benjamin Kildal, Jean-Christophe Richard, Olav Dalgard, Victoria Charlotte Simensen, Aliou Baldé, Lucie de Gastines, Marta del Álamo, Burç Aydin, Fridtjof Lund-Johansen, Mary-Anne Trabaud, Alpha Diallo, Bente Halvorsen, John-Arne Røttingen, Evelina Tacconelli, Yazdan Yazdanpanah, Inge C. Olsen, Dominique Costagliola, EU SolidAct study group

    Published 2023-01-01
    Get full text
    Article

Search Tools: